Stockreport

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 ...

Acrivon Therapeutics, Inc.  (ACRV) 
PDF AP3 identified mechanism of resistance to ACR-368, a clinical-stage CHK1/2 inhibitor, as well as a rational combination treatment to overcome resistance through sensiti [Read more]